Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA

The idea that you can drug RNA has attracted a variety of biotech startups interested in pioneering a new technology. And one of those biotechs looking to break new ground in the field just scooped up a $30 million round.